Integra Lifesciences Holdings Corp (NASDAQ:IART) VP Joseph Vinhais sold 6,800 shares of the stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $54.13, for a total value of $368,084.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Integra Lifesciences Holdings Corp (IART) opened at $56.14 on Thursday. The company has a debt-to-equity ratio of 1.85, a quick ratio of 1.51 and a current ratio of 2.36. The stock has a market capitalization of $4,413.73, a price-to-earnings ratio of 29.14, a price-to-earnings-growth ratio of 1.73 and a beta of 0.65. Integra Lifesciences Holdings Corp has a one year low of $40.51 and a one year high of $57.14.
Integra Lifesciences (NASDAQ:IART) last issued its quarterly earnings results on Tuesday, February 27th. The life sciences company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.08. The firm had revenue of $368.60 million during the quarter, compared to analyst estimates of $362.64 million. Integra Lifesciences had a return on equity of 16.94% and a net margin of 5.45%. The firm’s quarterly revenue was up 44.2% on a year-over-year basis. During the same period last year, the company posted $0.52 EPS. equities research analysts predict that Integra Lifesciences Holdings Corp will post 2.33 earnings per share for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Integra Lifesciences by 38.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,806 shares of the life sciences company’s stock worth $182,000 after acquiring an additional 1,054 shares in the last quarter. Zions Bancorporation bought a new stake in shares of Integra Lifesciences during the 3rd quarter worth $205,000. Xact Kapitalforvaltning AB bought a new stake in shares of Integra Lifesciences during the 4th quarter worth $311,000. Campbell Newman Asset Management Inc. boosted its stake in shares of Integra Lifesciences by 21.5% during the 4th quarter. Campbell Newman Asset Management Inc. now owns 6,964 shares of the life sciences company’s stock worth $333,000 after acquiring an additional 1,234 shares in the last quarter. Finally, Oppenheimer & Co. Inc. boosted its stake in shares of Integra Lifesciences by 25.2% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 7,293 shares of the life sciences company’s stock worth $368,000 after acquiring an additional 1,466 shares in the last quarter. 90.93% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Integra Lifesciences Holdings Corp (IART) VP Sells $368,084.00 in Stock” was originally published by BBNS and is owned by of BBNS. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://baseballnewssource.com/2018/03/15/integra-lifesciences-holdings-corp-iart-vp-sells-368084-00-in-stock/2037327.html.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.